Protara Therapeutics, Inc.

NasdaqGM TARA

Protara Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024

Protara Therapeutics, Inc. Return on Assets (ROA) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Protara Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2023 was -67.81%, a -196.30% change year over year.
Protara Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2022 was -22.89%, a 4.48% change year over year.
Protara Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2021 was -23.96%.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqGM: TARA

Protara Therapeutics, Inc.

CEO	Mr. Jesse Shefferman
IPO Date	Oct. 22, 2014
Location	United States
Headquarters	345 Park Avenue South
Employees	26
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

Key trends

Past 5 years